GLP-1RAs May Reduce Acute Care Use in Migraine Patients

For primary care physicians managing the complex intersection of metabolic health and neurology, new real-world data suggest glucagon-like peptide-1 receptor agonists (GLP-1RAs) may offer secondary benefits for patients with chronic migraine. Patients initiating GLP-1RAs for comorbid conditions like diabetes or obesity experience significantly lower rates of acute care utilization and medication escalation compared to those prescribed topiramate according to a new study scheduled for presentation at the American Academy of Neurology’s (AAN) 78th Annual Meeting.

“People with chronic migraine often end up in the emergency room or they need to try several preventive medications before finding one that can work for them,” said study investigator Vitoria Acar, MD, of the University of Sao Paulo in Brazil. “Seeing these patterns of lower use of emergency care and lower use of drugs to stop migraines or trying additional drugs to prevent migraines among people taking GLP-1 drugs for other conditions suggests that these therapies may help stabilize the disease burden in ways that we haven’t fully appreciated yet.”

Chronic migraine, defined as 15 or more headache days per month for at least 3 months, imposes a substantial burden on both patients and the healthcare system. Investigators utilized the TriNetX health-record database to compare 10,997 adults (mean age 48 years; 87.8% female) with chronic migraine who initiated a GLP-1RA, including semaglutide, liraglutide, and dulaglutide, against an equal number of patients starting topiramate, a standard first-line preventive.

The findings revealed GLP-1RA users were 10% less likely (23.7% vs 26.4%; Risk Ratio [RR], 0.90; 95% CI, 0.86-0.94) to visit the emergency department and 14% (RR, 0.86; 95% CI, 0.81-0.91) less likely to be hospitalized for any reason over a 12-month follow-up period. Furthermore, the GLP-1RA cohort demonstrated a 13% (RR, 0.87; 95% CI, 0.78–0.97) reduction in the risk of requiring nerve block procedures or triptan prescriptions to abort attacks.

One of the most striking findings for the primary care setting is the reduced need for "preventive-treatment escalation". Patients on GLP-1RAs were significantly less likely to be prescribed additional, often more intensive, migraine preventives. Specifically, compared to the topiramate group, GLP-1RA initiators were:

• 48% less likely to start valproate (RR, 0.52; 95% CI, 0.40–0.68)
• 42% less likely to start CGRP monoclonal antibodies (RR, 0.58; 95% CI, 0.52–0.65)
• 35% less likely to start tricyclic antidepressants (RR, 0.65; 95% CI, 0.55–0.77)
• 23% less likely to start gepants (RR, 0.77; 95% CI, 0.69–0.85)

While GLP-1RAs are well-known for weight loss, investigators hypothesize their benefits in migraine management may stem from anti-inflammatory and neurovascular effects. Acar highlighted chronic migraine often overlaps with obesity, insulin resistance, and depression, which can complicate traditional treatment paths. By addressing these underlying metabolic and inflammatory pathways, GLP-1RAs may influence migraine pathophysiology directly.

“Chronic migraine often overlaps with metabolic and inflammatory conditions such as obesity, insulin resistance, sleep apnea and depression, which can make treatment more difficult,” Acar said. “Early research is looking at whether GLP-1 drugs’ anti-inflammatory and neurovascular effects could play a role in migraine treatment, not just through weight loss.”

Despite the promising results, the investigators emphasize these findings show an association rather than causation. As an observational study, it could not account for dynamic changes occurring throughout the year, such as the exact degree of weight loss or specific lifestyle modifications. Furthermore, no randomized controlled trials have yet been conducted to specifically assess GLP-1RAs as a primary migraine preventive.

For the primary care physician, these results provide a nuanced view of GLP-1RA therapy in patients with multi-morbidities. While topiramate remains a standard of care, the potential for GLP-1RAs to reduce overall healthcare utilization and polypharmacy in migraine patients warrants further prospective evaluation.

References:

1. American Academy of Neurology: Neurology Resources | AAN. Aan.com. Published March 1, 2026. Accessed March 2, 2026. https://www.aan.com/PressRoom/Home/PressRelease/5321
2. Acar V, Franco M, Wang V, Yuan H, et al. GLP-1 Receptor Agonists and Chronic Migraine: A Real-World Cohort Study of Healthcare Utilization and Preventive Escalation. Presented at: American Academy of Neurology’s (AAN) 78th Annual Meeting; April 19-22, 2026; Chicago, Il.